Microalbuminuria: A common, independent cardiovascular risk factor, especially but not exclusively in type 2 diabetes

Journal of Hypertension, Supplement

Volumn 21, Issue 1, 2003, Pages

  Donnelly, Richard ^a,b   Yeung, Justin M C ^a   Manning, Gillian ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b DERBYSHIRE ROYAL INFIRMARY   (United Kingdom)

Author keywords

Endothelial dysfunction; Hypertension; Microalbuminuria; Type 2 diabetes

Indexed keywords

ALBUMIN; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; INDAPAMIDE; IRBESARTAN; PLACEBO;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CAUSE OF DEATH; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DRUG EFFICACY; ENDOTHELIUM CELL; HEART FAILURE; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; HYPERTENSION; INSULIN RESISTANCE; LOW DRUG DOSE; MICROALBUMINURIA; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SMOKING; TREATMENT OUTCOME; URINALYSIS; VASCULAR DISEASE;

ALBUMINURIA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIURETICS; HUMANS; HYPERTENSION; RISK FACTORS;

EID: 0037731843     PISSN: 09521178     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (53)

1. Kimmelstiel P, Wilson C. Intracapillary lesions in the glomeruli in the kidney. Am J Pathol 1936; 12:83-97.
2. Mogensen CE, Microalbuminuria, blood pressure and diabetic renal disease: origin and development of ideas. Diabetologia 1999; 42:263-285.
3. Mathiesen ER, Ronn B, Jensen T, Storm B, Deckert T. The relationship between blood pressure and urinary albumin excretion in the development of microalbuminuria. Diabetes 1990; 39:245-249.
4. Fioretto P, Mauer M, Brocco E, Velussi M, Frigato F, Muollo B, et al. Patterns of renal injury in NIDDM patients with microalbuminuria. Diabetologia 1996; 39:1569-1576.
5. Yokoyama H, Okudaira M, Otani T, Sato A, Miura J, Takaike H, et al. Higher incidence of diabetic nephropathy in type 2 than in type 1 diabetes in early-onset diabetes in Japan. Kidney Int 2000; 58:302-311.
6. Ballard DJ, Humphrey LL, Melton LJ, Frohnert PP, Chu PC, O_Fallon WM, et al. Epidemiology of persistent proteinuria in type 2 diabetes mellitus: population-based study in Rochester, Minnesota. Diabetes 1988; 37:405-412.
7. Hostetter TH. Prevention of end-stage renal disease due to type 2 diabetes. N Engl J Med 2001; 345:910-912.
8. Krolewski AS, Warram JH, Rand LI, Kahn CR. Epidemiologic approach to the etiology of type 1 diabetes mellitus and its complications. N Engl J Med 1987; 317:1390-1398.
9. Panzram G. Mortality and survival in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1987; 30:123-131.
10. Borch-Johnsen K, Andersen JK, Deckert T. The effect of proteinuria on relative mortality in Type 1 diabetic patients. Diabetologia 1985; 28:590-596.
11. Nelson RG, Pettit DJ, Carraher MJ, Baird HR, Knowler WC. Effect of proteinuria on mortality in NIDDM. Diabetes 1988; 37:1499-1504.
12. Gatling W, Knight C, Mullee MA, Hill RD. Microalbuminuria in diabetes: a population study of the prevalence and an assessment of three screening tests. Diabetic Med 1988; 5:343-347.
13. Klein R, Klein BEK, Moss SE. Prevalence of microalbuminuria in older-onset diabetes. Diabetes Care 1993; 16:1325-1330.
14. Gall MA, Rossing P, Skott P, Damsbo P, Vaag A, Bech K, et al. Prevalence of micro- and macroalbuminuria, arterial hypertension, retinopathy and large vessel disease in European Type 2 diabetic patients. Diabetologia 1991; 34:655-661.
15. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352:837-853.
16. Bennett PH, Lee ET, Lu M, Keen H, Fuller JH, for the WHO Multinational study group. Increased urinary albumin excretion and its associations in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 2001; 44 (Suppl 2):S37-S45.
17. Gall MA, Borch-Johnsen K, Hougaard P, Nielsen FS, Parving HH. Albuminuria and poor glycaemic control predict mortality in NIDDM. Diabetes 1995; 44:1303-1309.
18. Pell S, D'Alonzo CA. Factors associated with long-term survival of diabetics. JAMA 1970; 214:1833-1840.
19. Stephenson JM, Kenny S, Stevens LK, Fuller JH, Lee E. Proteinuria and mortality in diabetes: the WHO Multinational Study of Vascular Disease in Diabetes. Diabet Med 1995; 12:149-155
20. Mykkanen L, Zaccaro D J, Wagenknecht LE, Robins DC, Gabriel M, Haffner SM. Microalbuminuria is associated with insulin resistance in nondiabetic subjects. Diabetes 1998; 47:793-800.
21. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984; 310:356-360.
22. Schmitz A, Vaeth M. Microalbuminuria: a major risk factor in non-insulin-dependent diabetes: a 10-yr follow-up study of 503 patients. Diabet Med 1988; 5:126-134.
23. Stiegler H, Standl E, Schulz K, Roth R, Lehmacher W. Morbidity, mortality and albuminuria in type 2 diabetic patients: a 3-yr prospective study of a random cohort in general practice. Diabet Med 1992; 9:646-653.
24. Chan JC, Cheung CK, Cheung MY, Swaminathan R, Critchley JA, Cockram CS. Abnormal albuminuria as a predictor of mortality and renal impairment in Chinese patients with NIDDM. Diabetes Care 1995; 18:1013-1016.
25. Damsgaard EM, Froland A, Jorgensen OD, Morgensen CE. Prognostic value of urinary albumin excretion rate and other risk factors in elderly diabetic patients and non-diabetic control subjects surviving the first 5-years after assessment. Diabetologia 1993; 36:1030-1036.
26. Mattock MB, Barnes DJ, Viberti G, Keen H, Burt D, Hughes JM, et al. Microalbuminuria and coronary heart disease in NIDDM: an incidence study. Diabetes 1998; 47:1786-1792.
27. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in NIDDM: a systematic overview of the literature. Arch Intern Med 1997; 157:1413-1418.
28. Valmadrid CT, Klein R, Moss SE, Klein BEK. The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med 2000; 160:1093-1100.
29. Gerstein HC, Mann JFE, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and non-diabetic individuals. JAMA 2001; 286:421-426.
30. Roest M, Banga JD, Janssen WMT, Grobbee DE, Sixma JJ, de Jong PE, et al. Excessive urinary albumin levels are associated with future cardiovascular mortality in postmenopausal women. Circulation 2001; 103:3057-3061.
31. Gerstein HC, Mann JF, Pogue J, Dinneen SF, Halle JP, Hoogwerf B, et al., for the HOPE study investigators. Prevalence and determinants of microalbuminuria in high-risk diabetic and non-diabetic patients in the Heart Outcomes Prevention Evaluation Study. Diabetes Care 2000; 23 (Suppl 2): B35-B39.
32. Cirillo M, Senigalliesi I, Laurenzi M, Alfieri R, Stamler J, Stamler R, et al. Microalbuminuria in nondiabetic adults. Arch Intern Med 1998; 158:1933-1939.
33. Yudkin JS, Forrest RD, Jackson CA. Microalbuminuria as predictor of vascular disease in nondiabetic subjects. Lancet 1988; ii:530-533.
34. Agewall S, Wikstrand J, Ljungman S, Herlitz H, Fagerberg B. Does microalbuminuria predict cardiovascular events in nondiabetic men with treated hypertension? Risk Factor Intervention Study Group. Am J Hypertens 1995; 8:337-342.
35. Jager A, Kostense PJ, Ruhe HG, Heine RJ, Nijpels G, Dekker JM, et al Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all-cause mortality, especially among hypertensive subjects: 5-year follow-up of the Hoorn Study. Arterioscler Thromb Vasc Biol 1999; 19:617-624.
36. Damsgaard EM, Froland A, Jorgensen OD, Mogensen CE. Microalbuminuria as a predictor of increased mortality in elderly people. Br Med J 1990; 300:297-300.
37. Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S, Schroll M, Jensen JS. Urinary albumin excretion: an independent predictor of ischaemic heart disease. Arterioscler Thromb Vasc Biol 1999; 19:1992-1997.
38. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, KofoedEnevoldsen A. Albuminuria reflects widespread vascular damage: the Steno hypothesis. Diabetologia 1989; 32:219-226.
39. Gaede P, Vedel P, Parving H-H, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999; 353:617-622.
40. Parving H-H, Lehnert H, Mortensen JB, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345:870-878.
41. Idris I, Tyreman N, Gray S, Donnelly R. Losartan attenuates endothelial hyperpermeability responses to VPF and high glucose but not angiotensin II. Diabetologia 2002; 45:291-292.
42. Anavekar SN, Ludbrook A, Louis WJ, Doyle AE. Evaluation of indapamide in the treatment of hypertension. J Cardiovasc Pharmacol 1979; 1:389-394.
43. Lacourciere Y. Analysis of well-being and 24-hour blood pressure recording in a comparative study between indapamide and captopril. Am J Med 1988; 84(Suppl 1B):47-52.
44. Leonetti G, Rappelli A, Salvetti A, Scapellato L. Long-term effects of indapamide: final results of a two-year Italian multicenter study in systemic hypertension. Am J Cardiol 1990; 65:67H-71H.
45. Gambardella S, Frontoni S, Lala A, Felici MG, Spallone V, Scoppola A, et al. Regression of microalbuminuria in type II diabetics, hypertensive patients after long-term indapamide treatment. Am Heart J 1991; 122:1232-1238.
46. Molyneaux LM, Willey KA, Yue DK. Indapamide is as effective as captopril in the control of microalbuminuria in diabetes. J Cardiovasc Pharmacol 1996; 27:424-427.
47. Donnelly R, Lynda M, Molyneaux RN, Karen A, Willey RN, Yue DK. Comparative effects of indapamide and captopril on blood pressure and albumin excretion rate in diabetic microalbuminuria. Am J Cardiol 1996; 77:26B-30B.
48. Ambrosioni E, Safar M, Degaute JP, Malin PL, MacMahon M. Low-dose antihypertensive therapy with 1.5 mg sustained-release indapamide: results of randomised double-blind controlled study. J Hypertens 1998; 16:1677-1684.
49. Asmar R, Amah G, Crisan O, Haddad S. Efficacy and tolerance of indapamide sustained-release 1.5 mg on 24-h blood pressure in essential hypertension. Eur Heart J 1999; 1 (Suppl P):P21-P30.
50. Marre M. Indapamide SR 1.5 mg versus enalapril 10 mg in the regression of microalbuminuria in hypertensive type II diabetic patients. J Hypertens 1998; 16:S334.
51. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure (JNC-VI). Arch Intern Med 1997; 157:2413-2446.
52. Wodd Health Organization. International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J Hypertens 1999; 17:151-183.
53. American Diabetes Association. Diabetes Care 2002; 25(Suppl 1):S71-S73.